Copyright
©The Author(s) 2015.
World J Gastroenterol. Mar 14, 2015; 21(10): 3013-3019
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.3013
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.3013
Table 1 Main features of the study population at baseline
| Baseline feature | Dual therapy | Triple therapy | Normal range | P value |
| Age (yr) | 51.82 ± 11.40 | 56.65 ± 8.24 | 0.16 | |
| BMI | 24.65 ± 3.45 | 26.17 ± 3.55 | 18-25 | 0.08 |
| Male sex | 40/25 | 10/10 | ||
| Albumin (g/dL) | 4.11 ± 0.34 | 4.08 ± 0.49 | 3.5-5.0 | 0.95 |
| Bilirubin (mg/dL) | 0.78 ± 0.41 | 1.05 ± 0.21 | 0.3-1 | 0.06 |
| Platelets (× 109/L) | 190.29 ± 60.04 | 168.16 ± 51.08 | 140-440 | 0.18 |
| ALT (U/L) | 116.75 ± 88.69 | 82.88 ± 47.86 | 5-40 | 0.28 |
| GGT (U/L) | 72.16 ± 80.53 | 93.38 ± 77.62 | 10-40 | 0.06 |
| C/T or T/T IL28B genotype | 19.50% | 100% | ||
| Liver stiffness (kPa) | 8.61 ± 5.79 | 13.29 ± 8.57 | 0.002 | |
| HCV genotypes 1/4, n (%) | 24 (36.92) | 20 (100) | ||
| HCV genotypes 2/3, n (%) | 41 (63.08) | |||
| HCV RNA level (IU × 1000) | 3459.135 ± 5541.24 | 4924.462 ± 6799.737 | 0.72 |
- Citation: Stasi C, Piluso A, Arena U, Salomoni E, Montalto P, Monti M, Boldrini B, Corti G, Marra F, Laffi G, Milani S, Zignego AL. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. World J Gastroenterol 2015; 21(10): 3013-3019
- URL: https://www.wjgnet.com/1007-9327/full/v21/i10/3013.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i10.3013